Drug profile · INN
lazertinib mesylate
LAZCLUZE
- US status
- approved
- Patents linked
- 0
- News articles
- 0
Quick answer
lazertinib mesylate (LAZCLUZE) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.
Key facts
INN lazertinib mesylate
Brand LAZCLUZE
Route ORAL
Formulation TABLET
Frequently asked questions
What is lazertinib mesylate?
lazertinib mesylate (LAZCLUZE) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for lazertinib mesylate?
LAZCLUZE is a marketed brand name for lazertinib mesylate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of lazertinib mesylate?
lazertinib mesylate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.